White Pine Capital LLC Decreases Stock Position in Surmodics, Inc. (NASDAQ:SRDX)

White Pine Capital LLC cut its stake in Surmodics, Inc. (NASDAQ:SRDX) by 4.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,343 shares of the company’s stock after selling 1,932 shares during the period. White Pine Capital LLC owned about 0.29% of Surmodics worth $1,503,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new stake in Surmodics during the 4th quarter worth about $163,000. Strs Ohio lifted its holdings in Surmodics by 97.2% during the 4th quarter. Strs Ohio now owns 7,100 shares of the company’s stock worth $258,000 after buying an additional 3,500 shares during the last quarter. Moody National Bank Trust Division lifted its holdings in Surmodics by 14.8% during the 4th quarter. Moody National Bank Trust Division now owns 10,341 shares of the company’s stock worth $376,000 after buying an additional 1,331 shares during the last quarter. Panagora Asset Management Inc. purchased a new stake in Surmodics during the 3rd quarter worth about $683,000. Finally, Los Angeles Capital Management LLC lifted its holdings in Surmodics by 149.2% during the 3rd quarter. Los Angeles Capital Management LLC now owns 34,916 shares of the company’s stock worth $1,120,000 after buying an additional 20,906 shares during the last quarter. 96.63% of the stock is currently owned by hedge funds and other institutional investors.

Surmodics Stock Performance

Shares of Surmodics stock remained flat at $26.17 on Friday. The stock had a trading volume of 22,671 shares, compared to its average volume of 105,795. Surmodics, Inc. has a fifty-two week low of $16.79 and a fifty-two week high of $39.41. The company has a current ratio of 4.84, a quick ratio of 3.97 and a debt-to-equity ratio of 0.24. The firm has a market cap of $372.66 million, a PE ratio of 68.87 and a beta of 1.01. The business has a 50-day moving average price of $28.77 and a 200 day moving average price of $31.68.

Analysts Set New Price Targets

A number of brokerages have issued reports on SRDX. Needham & Company LLC reaffirmed a “buy” rating and set a $47.00 price target on shares of Surmodics in a report on Wednesday, April 10th. StockNews.com downgraded Surmodics from a “strong-buy” rating to a “buy” rating in a report on Wednesday.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).